CAS NO: | 2687961-04-0 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
Cas No. | 2687961-04-0 |
别名 | 盐酸左卡尼汀:,(R)-Carnitine-d9 chloride; Levocarnitine-d9 chloride |
Canonical SMILES | [2H]C([2H])([N+](C([2H])([2H])[2H])(C[C@@H](CC(O)=O)O)C([2H])([2H])[2H])[2H].[Cl-] |
分子式 | C7H7D9NO3 • Cl |
分子量 | 206.7 |
溶解度 | DMF: 15 mg/ml,DMSO: 20 mg/ml,Ethanol: 25 mg/ml,PBS (pH 7.2): 10 mg/ml |
储存条件 | -20буC |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | L-Carnitine-d9is intended for use as an internal standard for the quantification of L-carnitine by GC- or LC-MS. L-Carnitine is a conditionally essential nutrient.1It is obtained from dietary sources or through the metabolism of lysine and methionine.2,3L-Carnitine facilitates the transport of long-chain fatty acids into the mitochondrial matrix for β-oxidation, has other diverse roles on metabolism, and is involved in the maintenance of coenzyme A stores. Plasma and/or tissue levels of L-carnitine are decreased in primary L-carnitine deficiency, a disorder characterized by impaired fatty acid oxidation, with symptoms varying depending on whether it is systemic or muscle-specific.1Serum and tissue levels of L-carnitine are also reduced in secondary L-carnitine deficiencies caused by a variety of hereditary defects or acquired disorders. 1.Seim, H., Eichler, K., and Kleber, H.-P.L(-)-Carnitine and its precursor, γ-butyrobetaineNutraceuticals in Health and Disease Prevention217-256(2001) 2.Vaz, F.M., and Wanders, R.J.A.Carnitine biosynthesis in mammalsBiochem. J.361(Pt 3)417-429(2002) 3.Fu, L., Huang, M., and Chen, S.Primary carnitine deficiency and cardiomyopathyKorean. Circ. J.43(12)785-792(2013) |